Eszopiclone
Brand names: Lunesta, Eszopiclone
At a glance
- Medicare prescriptions, 2024
- 548,375
- Medicare drug cost
- $12.9M
- Average cost per prescription
- $23.58
- Clinicians who prescribed it
- 25,742
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
LUNESTA ® (eszopiclone) is indicated for the treatment of insomnia. In controlled outpatient and sleep laboratory studies, LUNESTA administered at bedtime decreased sleep latency and improved sleep maintenance. The clinical trials performed in support of efficacy were up to 6 months in duration. The final formal assessments of sleep latency and maintenance were performed at 4 weeks in the 6-week study (adults only), at the end of both 2-week studies (elderly only) and at the end of the 6-month study (adults only).
From the FDA-approved prescribing information (label dated January 2025). Full labels on DailyMed (opens in a new tab)
Boxed warning
WARNING: COMPLEX SLEEP BEHAVIORS Complex sleep behaviors including sleep-walking, sleep-driving, and engaging in other activities while not fully awake may occur following use of LUNESTA. Some of these events may result in serious injuries, including death. Discontinue LUNESTA immediately if a patient experiences a complex sleep behavior. WARNING: COMPLEX SLEEP BEHAVIORS See full prescribing information for complete boxed warning. Complex sleep behaviors including sleep-walking, sleep-driving, and engaging in other activities while not fully awake may occur following use of LUNESTA. Some of these events may result in serious injuries, including death. Discontinue LUNESTA immediately if a patient experiences a complex sleep behavior.
The FDA’s strongest warning on a label. It doesn’t mean the drug is unsafe for most people; talk to your doctor or pharmacist before stopping or changing any medicine.
Who prescribes it
- Family Medicine 28.9%
- Internal Medicine 21.3%
- Psychiatry 12.5%
- Nurse Practitioners 11.8%
- Psychiatric Nurse Practitioners 7.7%
- Physician Assistants 5.1%
- Pulmonology 2.1%
- Neurology 2.1%
- Sleep Medicine 1.6%
- Pain Medicine 1.4%
- General Practice 0.7%
- Child & Adolescent Psychiatry 0.6%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions rose 70% from 2019 to 2024.
Biggest change by state since 2019
- Arkansas +163%
- Alabama +139%
- Georgia +116%
- South Carolina +109%
- Louisiana +109%
- New Jersey (smallest change) +24%
- Minnesota (smallest change) +30%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 4 makers on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
Pd-Rx Pharmaceuticals, Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 3 mg | blue round tablet, 6 mm | K 85 |
Remedyrepack Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 2 mg | white round tablet, 6 mm | L35 |
St Mary's Medical PArk Pharmacy
| Strength | Looks like | Imprint |
|---|---|---|
| 2 mg | white round tablet, 6 mm | 383 G |
Waylis Therapeutics LLC
| Strength | Looks like | Imprint |
|---|---|---|
| 1 mg | blue round tablet, 6 mm | S190 |
| 2 mg | white round tablet, 6 mm | S191 |
| 3 mg | blue round tablet, 6 mm | S193 |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
No industry payments to clinicians named this drug in 2025.
Recalls and shortages
Not on the FDA drug shortage list.
2 recalls since 2020
- Jun 2024 · Dr. Reddy's Laboratories, Inc. · Class III
Failed Impurities/Degradation Specifications: Related Substances - Jun 2022 · Macleods Pharma Usa Inc · Class II
Shortfill: customer complaints of one to three tablets were reported missing from 30 count bottles.
Recalls usually affect specific lots from one maker, not every version of a drug. Class I is the most serious; most drug recalls are Class II. FDA recalls (opens in a new tab)
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.